PolyPid’s Insider Moves Boost Confidence Ahead of 2026 FDA Approval of D‑PLEX100
PolyPid’s insider buying and FDA waiver for D‑PLEX100 signal a strong 2026–29 growth push, positioning its novel β‑lactam/β‑lactamase combo to curb AMR and unlock valuation upside.
3 minutes to read